PAS-004

→ It didn’t take long for Natalie Holles to rebound after the decision to wind down operations at her previous company. She has replaced Elisabet de los Pinos as CEO of Aura Biosciences , which is investigating belzupacap sarotalocan (or bel-sar ) in early choroidal melanoma. Aura indicated that it wanted to enroll 100 patients for the Phase 3 CoMpass study, and the Boston biotech says it has signed up 86 patients so far. Holles ran Audentes Therapeutics after it was purchased by Astellas and subsequently known as Astellas Gene Therapies . The company and the field itself were severely rattled by the deaths of four patients in a trial for a rare disease called X-linked myotubular myopathy. Holles launched Third Harmonic Bio in 2022 with a $105 million Series B in addition to a previously undisclosed $50 million Series A, and when nobody else dared, Third Harmonic went public six months later. But in April 2025, the biotech said it would close and sell its lead program THB335 . Holles has also jumped to the board of directors at LeonaBio , along with Fred Callori and ex- Merus COO Peter Silverman . She currently chairs the board at Renasant Bio , a kidney health biotech that raised $54.5 million in a seed round last year. → Former Celgene boss Mark Alles has handed over CEO duties to Aran Maree at Los Angeles-based ADC maker TORL BioTherapeutics . Alles will still chair the board at TORL, which has promoted Christine Loggins to COO and Steve Ritland to CSO this year while bringing in Vince Ruiz as general counsel. Maree had multiple roles over an 18-year period at J&J before taking the CMO job at TORL in October 2024. TORL has corralled more than $450 million in financing, including a $96 million Series C in October 2025 that fell short of its earlier rounds. → Pfizer has poached an obesity expert from Novo Nordisk . Rahul Ganguly has taken the role of VP and US obesity medical lead at the US giant, according to a post on LinkedIn, and will doubtless help guide development of the obesity programs Pfizer obtained when it bought Metsera last year — beating Novo to the prize . Ganguly left Novo at the end of last year, having spent over a decade at the Danish company. He initially oversaw health economic strategy for Novo’s diabetes and obesity operations, and rose to become VP of cardiovascular and emerging therapy areas. Before that, he spent 11 years at GSK . → Former Novo Nordisk exec Camilla Sylvest is on the verge of clinching a spot on the board of directors at another one of its competitors. She’s slated to become the newest board member at Zealand Pharma , which said last week that it saw comparable weight loss to Wegovy with its Boehringer Ingelheim -partnered obesity med survodutide in a Phase 3 trial. Sylvest had been EVP, commercial strategy and corporate affairs before she ended a 29-year career with Novo in April 2025. She also sits on the board at argenx , and she emphasized in a LinkedIn post that she would concentrate solely on these types of roles for the next two to three years. → The president of Merck ’s manufacturing division announced his retirement in a lengthy LinkedIn post . Sanat Chattopadhyay spent the last decade in this position, and 27-year Merck vet Dave Maraldo will take his place. Chattopadhyay came to Merck in 2009. “Together, we helped shape some of the company’s most defining chapters: transforming our vaccines operations, launching Keytruda in record time and scaling it up to be the largest monoclonal antibody ever produced for an acute care product, as well as expanding our global biologics and vaccines capabilities to reach more patients around the world,” Chattopadhyay wrote, adding, “We created a resilient manufacturing and supply network designed not just for today, but for the patients who will depend on it for decades to come.” → Astellas has found its new chief strategy officer after Adam Pearson stepped down in March. Takahiko Iwaya previously held a number of roles across Japan’s Ministry of Health, Labour and Welfare, J&J and Sanofi . He is currently president of Sanofi Japan and also chairs the European Federation of Pharmaceutical Industries and Associations in Japan. He is scheduled to step down from both roles in June. Pearson had joined Astellas in 2004, climbing to chief strategy officer in 2023. He led Astellas’ buyout of Iveric Bio that gave it the eye drug Izervay . In the interim, Astellas’ head of corporate strategy Peter Sandor has been serving as chief strategy officer. → This is Nathan Jorgensen ’s last day as CFO of Voyager Therapeutics , according to an SEC filing . It’s the second major resignation at Voyager in the last several months after medical chief Toby Ferguson packed his bags. Ferguson’s LinkedIn page says that he’s the new SVP of the neuroscience therapeutic area at Alnylam . The RNAi pioneer has several neuro candidates in its pipeline, including mivelsiran for Alzheimer’s and ALN-HTT02 for Huntington’s disease. Like Ferguson, Jorgensen is resigning less than two years into his tenure. → Christopher Missling has been fired as CEO of New York-based neuro biotech Anavex Life Sciences , and senior advisor Terrie Kellmeyer has stepped in as interim chief. An SEC filing says that Missling was terminated “for cause” due to “conduct that the Special Committee believed was inconsistent with company policy.” Last year around this time, Peer Review told you that Kellmeyer had joined Aardvark Therapeutics as SVP of regulatory affairs after a stint with Anavex as SVP of clinical development. Anavex has drawn criticism for altering the primary endpoints in a topline readout for its Alzheimer’s drug blarcamesine in 2022. Undeterred, Anavex said in March that it’s sent more data to the FDA to boost its NDA chances. → Halozyme Therapeutics , the drug delivery technology company , has tapped one of its partner’s executives to become its next CFO. J&J’s head of IR Darren Snellgrove will get started on June 8. Halozyme has worked with J&J for years, helping the healthcare giant deliver Darzalex Faspro under the skin, broadening its use beyond the original injectable formulation. Snellgrove was succeeded by Ryan Koors on Thursday. Koors was previously CFO for J&J Innovative Medicine ’s global R&D. → We know where Stefan Irion is headed after we told you about his departure from BlueRock Therapeutics last week. He has succeeded co-founder Alex Ng as CSO of GC Therapeutics , a stem cell startup from the lab of George Church (hence the name) that broke cover in September 2024 with $75 million in financing. Ng will still be part of the team as chief innovation officer. “Cell therapy’s first generation proved engineered cells can durably treat disease. The next generation has to do something more ambitious: not just replace cells, but reprogram sick and aged cells into young, healthy ones and reach far more patients than today’s approaches allow,” Irion wrote on LinkedIn . “That’s exactly what drew me to GCT.” → Doretta Mistras is leaving after two years as CFO of Viatris , and chief accounting officer/corporate controller Paul Campbell is taking over . Campbell was with Mylan for 18 years before the merger with Upjohn to create Viatris. The generics giant posted Q1 results on Thursday that beat consensus estimates, and shares $VTRS hit a 52-week high. → Just a dream and the wind to carry him : Flagship ’s circular RNA startup Sail Biomedicines has recruited Gene Marcantonio as CMO. Marcantonio ran what’s now known as Rycarma Therapeutics from 2022-24 after nearly five years as the Forbion -backed biotech’s president and CMO. During a decade at Merck, he was promoted to associate VP, translational lead for infectious diseases, vaccines and immunology. → California cell therapy maker Kyverna Therapeutics has another new executive, naming Nadia Dac as its chief commercial officer. Dac started Monday, as the biotech seeks the first treatment approval for stiff person syndrome . She joined from the same post at Omeros , where she led the launch of a treatment for a stem cell transplant-associated condition. Prior to that, she also led the market entry of migraine prevention drug Vyepti at Alder BioPharmaceuticals . → MBX Biosciences has also hired a chief commercial officer as it gears up for Phase 3 studies of its hypoparathyroidism drug. Mark Soued spent 20 years with Pfizer before he moved over to Alnylam as head of global commercial. He had been head of US for Yvonne Greenstreet ’s crew since March 2024. MBX’s stock $MBX doubled in September 2025, when it disclosed positive Phase 2 data for canvuparatide . → Diagonal Therapeutics is turning to a recent M&A finance whiz to lead its growth. Jonathan Piazza helped lead Orbital Therapeutics to an exit to Bristol Myers Squibb and is quickly picking up another CFO role. Diagonal noted his quarter-century of experience in “company building, strategic finance, capital markets and M&A.” He joins with a recently bolstered balance sheet, thanks to a $125 million Series B for its rare bleeding disorder drug that will be tested in additional indications down the road. → The DNA damage response experts at Artios Pharma have selected Jeremy Fitch as CBO, Michael Alrutz as general counsel, and Guy Ruble as VP, regulatory affairs. Fitch joined Eli Lilly in 1992, and he just finished his career at the Indianapolis pharma with a year as VP, corporate business development transactions, immunology. Alrutz is the latest newcomer from Chimerix , where he was general counsel, secretary and chief compliance officer. We mentioned in February that three other senior leaders followed Artios CEO Mike Andriole from Chimerix. And Ruble is a 22-year Lilly vet who had the same job title at Iovance Biotherapeutics . → OncoNano CEO Kartik Krishnan has stepped down to take the CMO post at Miami-based Pasithea Therapeutics . Krishnan was elevated to the top spot in 2024, and OncoNano formed an alliance with Gilead at the start of this year that could be worth as much as $300 million. He’s also been CMO of Gilead’s longtime partner Arcus Biosciences from 2019-22. Krishnan will draw upon his knowledge of MEK inhibitors as Pasithea’s lead program PAS-004 goes through early-stage testing. His big project at Genentech was a MEK inhibitor called cobimetinib that was approved in 2015 and marketed as Cotellic . → Robert Blaustein has been named CMO at Immutrin , a Cambridge, UK-based amyloidosis biotech that recently captured an $87 million Series A from Frazier Life Sciences , SR One and others. Blaustein had a 15-year run at Merck, working his way up to associate VP and section head for atherosclerosis. In January 2025, we informed you about his appointment as chief development officer at Edgewise Therapeutics . → Tenax Therapeutics has welcomed a new chief commercial officer after the appointment of CFO Thomas Staab last month. AbbVie vet Timothy Healey ran the commercial team at Eversana Life Science Services for six years and was SVP, commercial for Lantheus . → Tris Pharma has promoted Jim Potenziano to chief science and development officer. Potenziano had served as VP, medical science and information, and was described in a press release as “the ideal leader to bring together the full breadth of Tris’ capabilities” by CEO Ketan Mehta . An NDA is on the horizon for Tris’ acute pain drug cebranopadol . → Spruce Biosciences has lined up Brian Walls as VP, market access, and Darren Johnson as VP, commercial operations. They held the same positions at Applied Therapeutics , which was foiled by a CRL for its galactosemia drug and would later be acquired by Cycle Pharma . They also worked together at Reata Pharmaceuticals until Biogen bought the Skyclarys maker for more than $7 billion. Spruce is developing a therapy for Sanfilippo syndrome type B and hopes to submit a BLA by the fourth quarter. → Jeito Capital is padding its leadership team. Fresh off a $1.2 billion sophomore fund , the Paris-based firm is now strengthening its BD and IR functions along with its talent oversight. Former Blackstone Life Sciences deputy operating chief Elaine Caughey has joined Jeito as partner of BD and IR. Meanwhile, former Oxford Science Enterprises chief talent officer Sarah Shackelton is becoming partner of talent at the Rafaèle Tordjman -led biotech investment fund. The partners will work with portfolio companies on business development and leadership and board development, respectively. → Tim Walbert has racked up multiple board appointments since orchestrating one of the largest drugmaker M&A deals of the past five years, but the former Horizon Therapeutics CEO still hasn’t outlined a full-time executive role at a biopharma. Instead, he’s continuing to line up more advisory positions. Patient Square Capital is his next destination. “We have known Tim for a long time and believe that his depth of experience will be an exceptional resource to our team and our portfolio companies as we expand our investment activities in the therapeutics sector,” Patient Square managing partner Jim Momtazee said in a press release . Walbert has taken his industry chops to the boards of Mirum Pharmaceuticals , Latigo Biotherapeutics , BioMarin and others. → CAR-T innovator Carl June leads a cast of characters that will help out Legend Biotech as scientific advisors. Georg Schett , Renier Brentjens , Ottimo Pharma ’s Spencer Fisk , Maximilian Konig and Anthony Polverino are also involved. “These advisors bring an exceptional breadth of experience that will help guide our scientific priorities and identify new opportunities for innovation,” Legend CEO Ying Huang said in a statement . → Cancer biotech Actuate Therapeutics has added Martin Huber to its board of directors. Huber became CEO of Mersana Therapeutics at a time when the biotech hit a particularly rough patch with patient deaths and clinical failures . He then sold Mersana to Day One Biopharmaceuticals , which was scooped up by Servier for $2.5 billion. Elizabeth Cairns and Lei Lei Wu also contributed to this edition.

MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer (CMO) of the Company, effective May 1, 2026. Dr. Krishnan will oversee all clinical development and medical strategy as the Company advances PAS-004 through the clinic for the treatment of neurofibromatosis type 1 (NF1) associated plexiform and cutaneous neurofibromas. “We are delighted to welcome Dr. Krishnan, who is recognized for his strategic approach to clinical development and commitment to improving patient outcomes, to our executive leadership team. Dr. Krishnan has a proven record of advancing novel therapies from early discovery through late-stage clinical development and regulatory approval at both global biopharmaceutical organizations and smaller biotech companies,” said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. “We believe his experience developing cobimetinib, a FDA-approved MEK inhibitor, is particularly relevant to our mission, and that his expertise will directly benefit the progression of our PAS-004 program.” Dr. Krishnan commented, “I am honored to join Pasithea at this point in the Company’s evolution, and excited for the opportunity to lead the development of PAS-004 in NF1 and potentially for other rare and pediatric diseases. PAS-004 has demonstrated a differentiated pharmacokinetic (PK) pro may hit the sweet spot between safety, tolerability and efficacy. Given my familiarity with the development of cobimetinib, I understand the broad potential of a safe, well-tolerated MEK inhibitor for NF1 patients and other rare and pediatric diseases.” Dr. Krishnan has over 20 years of experience in clinical development, pharmacovigilance, clinical operations, regulatory affairs, and R&D strategy. Prior to joining Pasithea, Dr. Krishnan was Chief Executive Officer at OncoNano Medicines, a privately held company developing anti-cancer assets. Prior to that, Dr. Krishnan was Chief Medical Officer at Arcus Biosciences, a discovery and clinical development company focusing on combination therapies in immuno-oncology. Earlier in his career, he held various clinical development and medical director roles of increasing responsibility at companies including, Astex Pharmaceuticals, Genentech, Five Prime Therapeutics, BioMarin, and Amgen. Prior to joining industry, Dr. Krishnan held a faculty position in the Department of Pediatrics at the University of Arizona, with both clinical and primary research responsibilities. While at Genentech, Dr. Krishnan was an integral part of the clinical team for cobimetanib (Cotellic™), contributing to the approval in the United States and Europe in 2015, for treatment of BRAF V600E mt or BRAF V600K mt melanoma in combination with vemurafenib (Zelboraf™). In addition, Dr. Krishnan worked to establish development opportunities for this MEK inhibitor beyond melanoma, including monotherapy work in diseases such as Langerhans cell histiocytosis (for which cobimetinib was approved in 2022) and novel combinations in breast and colon cancer. Dr. Krishnan received his B.A. in History (with Distinction) from the University of Virginia. He completed his M.D. and Ph.D. in Molecular, Biochemical and Biophysical Studies at Columbia University. His Ph.D. studies were completed in the lab of Dr. John Krolewski, focusing on JAK/STAT signaling in the interferon pathway. Dr. Krishnan trained in pediatrics at UCLA and in pediatric hematology and oncology at the Johns Hopkins University and the National Cancer Institute. About Pasithea Therapeutics Corp. Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in patients with advanced cancer (NCT06299839), and a Phase 1/1b clinical trial in patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas with symptomatic and inoperable, incompletely resected, or recurrent PN (NCT06961565). Forward Looking Statements This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company’s ongoing Phase 1 clinical trial of PAS-004 in advanced cancer patients, the Company’s ongoing Phase 1/1b clinical trial of PAS-004 in adult NF1 patients, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company’s plans, assumptions, expectations, beliefs and objectives, the success of the Company’s current and future business strategies, product development, pre-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth and financing opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission. Thus, actual results could be materially different. The Company undertakes no obligation to update these statements, whether as a result of new information, future events, or otherwise, after the date of this release, except as required by law. Pasithea Therapeutics Contact Patrick Gaynes Investor Relations pgaynes@pasithea.com